Patient-reported outcomes in DNA mismatch repair deficient/microsatellite instability high metastatic colorectal cancer treated with nivolumab: CheckMate 142

被引：0

作者：

Michael, Overman ^{[1
]}

Shital, Kamble ^{[2
]}

Rebecca, Moss ^{[2
]}

Fiona, Taylor ^{[3
]}

Gregory, Maglinte ^{[2
]}

James, Shaw ^{[2
]}

Kim, Cocks ^{[3
]}

Erin, Mann ^{[3
]}

Christine, Yip ^{[3
]}

Thierry, Andre ^{[4
]}

机构：

[1] MD Anderson Canc Ctr, Houston, TX USA

[2] Bristol Myers Squibb, Lawrence Township, NJ USA

[3] Adelphi Values, Boston, MA USA

[4] Hop St Antoine, AP HP, Paris, France

来源：

ANNALS OF ONCOLOGY | 2017年 / 28卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P-308

引用

页数：2

共 50 条

[41] Cost-effectiveness analysis of pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer
Liu, Tong
Liu, Shuang
Guan, Shangwei
Tai, Yu
Jin, Yao
Dong, Mei
[J]. JOURNAL OF CHEMOTHERAPY, 2023, 35 (08) : 745 - 752
[42] A phase 3 study of nivolumab (NIVO), NIVO plus ipilimumab (IPI), or chemotherapy for microsatellite instability-high (MSI-H)/mismatch repair-deficient (dMMR) metastatic colorectal cancer (mCRC): CheckMate 8HW
Andre, T.
Van Cutsem, E.
Elez, E.
Bennouna, J.
de la Fouchardiere, C.
Yoshino, T.
Jensen, L.
Mendez, G.
Li, J.
Goekkurt, E.
Abdullaev, S.
Chen, T.
Lei, M.
Lonardi, S.
[J]. ANNALS OF ONCOLOGY, 2022, 33 : S250 - S250
[43] Microsatellite instability as a predictor of a mutation in a DNA mismatch repair gene in familial colorectal cancer
Liu, T
Wahlberg, S
Burek, E
Lindblom, P
Rubio, C
Lindblom, A
[J]. GENES CHROMOSOMES & CANCER, 2000, 27 (01): : 17 - 25
[44] Status of Testing for High-Level Microsatellite Instability/Deficient Mismatch Repair in Colorectal Carcinoma
Hamilton, Stanley R.
[J]. JAMA ONCOLOGY, 2018, 4 (02)
[45] Nivolumab ± ipilimumab in treatment (tx) of patients (pts) with metastatic colorectal cancer (mCRC) with and without high microsatellite instability (MSI-H): CheckMate-142 interim results.
Overman, Michael J.
Kopetz, Scott
McDermott, Raymond S.
Leach, Joseph
Lonardi, Sara
Lenz, Heinz-Josef
Morse, Michael A.
Desai, Jayesh
Hill, Andrew
Axelson, Michael D.
Moss, Rebecca Anne
Lin, Chen-Sheng
Goldberg, Monica
Andre, Thierry
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
[46] Systemic treatment of mismatch repair deficient/microsatellite instability-high metastatic colorectal cancerdsingle versus double checkpoint inhibition
Marinelli, D.
Sabatini, A.
Bengala, E.
Ciurluini, F.
Picone, V.
Santini, D.
Pietrantonio, F.
Rossini, D.
Cremolini, C.
[J]. ESMO OPEN, 2024, 9 (06)
[47] PATIENT-REPORTED OUTCOMES IN THE GARNET TRIAL IN PATIENTS WITH ADVANCED OR RECURRENT MISMATCH REPAIR DEFICIENT SOLID TUMORS TREATED WITH DOSTARLIMAB
Kristeleit, Rebecca
Mathews, Cara
Redondo, Andres
Pennington, Kathryn
Boklage, Susan
Brown, Jubilee
[J]. ONCOLOGY NURSING FORUM, 2022, 49 (02) : E57 - E58
[48] The cost-effectiveness analysis of serplulimab versus regorafenib for treating previously treated unresectable or metastatic microsatellite instability-high or deficient mismatch repair colorectal cancer in China
Ma, Yue
Zhou, Jiting
Ye, Yuxin
Wang, Xintian
Ma, Aixia
Li, Hongchao
[J]. FRONTIERS IN ONCOLOGY, 2023, 13
[49] RECIST and iRECIST criteria for the evaluation of nivolumab plus ipilimumab in patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: the GERCOR NIPICOL phase II study
Cohen, Romain
Bennouna, Jaafar
Meurisse, Aurelia
Tournigand, Christophe
De La Fouchardiere, Christelle
Tougeron, David
Borg, Christophe
Mazard, Thibault
Chibaudel, Benoist
Garcia-Larnicol, Marie-Line
Svrcek, Magali
Vernerey, Dewi
Menu, Yves
Andre, Thierry
[J]. JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 (02)
[50] Immune Checkpoint Inhibition in Metastatic Colorectal Cancer Harboring Microsatellite Instability or Mismatch Repair Deficiency
Cohen, Romain
Colle, Raphael
Pudlarz, Thomas
Heran, Maximilien
Duval, Alex
Svrcek, Magali
Andre, Thierry
[J]. CANCERS, 2021, 13 (05) : 1 - 10

← 1 2 3 4 5 →